menu

COVID-19: Differentiating Disease Course and Updates on Treatment

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

COVID-19: Differentiating Disease Course and Updates on Treatment

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Clinicians treating patients in outpatient, urgent care, and emergent care settings who encounter patients with mild to moderate disease are tasked with providing optimal care to prevent disease progression. Drs. Charles Vega and David Cennimo take us through the spectrum of COVID-19 disease and identify available treatment options for your high-risk patients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Charles P. Vega, MD
    Clinical Professor, Family Medicine
    Associate Dean, School of Medicine
    University of California, Irvine
    Orange, CA

    Consulting Fees: GlaxoSmithKline, Johnson & Johnson

    Faculty:
    David J. Cennimo, MD, FACP, FAAP, FIDSA
    Associate Dean of Education
    Associate Professor of Medicine & Pediatrics
    Rutgers New Jersey Medical School
    New Brunswick, NJ

    No relevant relationships reported.

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Nick Lombardi has ownership interest in Vertex Pharmaceuticals.
    • Libby Lurwick has nothing to disclose.
    • Jay Runyon has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the COVID-19 disease course and identify treatment options for outpatients with mild to moderate COVID-19
    • Evaluate current and evolving treatment options for COVID-19 in emergent, urgent, and outpatient settings
  • Target Audience

    This activity is designed to meet the educational needs of primary care physicians, urgent care providers, nurse practitioners, physician assistants, and pharmacists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 10/14/2023. PAs should only claim credit commensurate with the extent of their participation.

    Global Learning Collaborative (GLC) designates this activity for 0.25 contact hours/0.025 CEUs by Global Learning Collaborative (GLC).

    The Universal Activity Number for this program is UAN JA0006235-0000-22-044-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by an independent educational grant from Merck.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Clinicians treating patients in outpatient, urgent care, and emergent care settings who encounter patients with mild to moderate disease are tasked with providing optimal care to prevent disease progression. Drs. Charles Vega and David Cennimo take us through the spectrum of COVID-19 disease and identify available treatment options for your high-risk patients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Charles P. Vega, MD
    Clinical Professor, Family Medicine
    Associate Dean, School of Medicine
    University of California, Irvine
    Orange, CA

    Consulting Fees: GlaxoSmithKline, Johnson & Johnson

    Faculty:
    David J. Cennimo, MD, FACP, FAAP, FIDSA
    Associate Dean of Education
    Associate Professor of Medicine & Pediatrics
    Rutgers New Jersey Medical School
    New Brunswick, NJ

    No relevant relationships reported.

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Nick Lombardi has ownership interest in Vertex Pharmaceuticals.
    • Libby Lurwick has nothing to disclose.
    • Jay Runyon has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the COVID-19 disease course and identify treatment options for outpatients with mild to moderate COVID-19
    • Evaluate current and evolving treatment options for COVID-19 in emergent, urgent, and outpatient settings
  • Target Audience

    This activity is designed to meet the educational needs of primary care physicians, urgent care providers, nurse practitioners, physician assistants, and pharmacists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 10/14/2023. PAs should only claim credit commensurate with the extent of their participation.

    Global Learning Collaborative (GLC) designates this activity for 0.25 contact hours/0.025 CEUs by Global Learning Collaborative (GLC).

    The Universal Activity Number for this program is UAN JA0006235-0000-22-044-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by an independent educational grant from Merck.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule6 Dec 2022